Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dyne Therapeutics, Inc. (DYN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.96+1.05 (+7.04%)
At close: 4:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

    - Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne’s Co-lead Candidates into the Clinic - - Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetica

  • Insider Monkey

    Where Do Hedge Funds Stand On Dyne Therapeutics, Inc. (DYN)?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of […]

  • GlobeNewswire

    Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

    - Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - - Event also Features Presentations and Commentary by Leading Neuromuscular Disease Experts, Valeria Sansone, M.D., Ph.D. and John Day, M.D., Ph.D. - WALTHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for

Advertisement
Advertisement